The National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH) is seeking a senior-level scientist with expertise in medications development, experience in design methodology of clinical trials, and knowledge of the Food and Drug Administration’s regulations to lead the Institute’s Division of Therapeutics and Medical Consequences (DTMC). As a federal biomedical research institution, NIDA's mission is to lead the Nation in bringing the power of science to bear on drug abuse and addiction. Specifically, NIDA seeks to understand the biomedical and social causes and consequences of drug addiction throughout the world.
As one of NIDA’s four extramural research divisions, DTMC’s primary goal is to facilitate the development of therapies to treat substance use disorders (SUDs). The Division also investigates the medical consequences of drug abuse, in particular that of HIV/AIDS; the Division’s work is highly impactful. For example, DTMC designed, funded, and executed the clinical trials that led to the approval of Nasal Narcan® to treat opiate overdose.
This is a Scientific Executive position that offers a unique and challenging opportunity to direct an extramural scientific program of national and international scope within NIDA. As a Scientific Executive, the Director, DTMC, is one of the eight senior leaders at NIDA and a key advisor to the Institute Director. The Director, DTMC, provides senior leadership for the development and administration of an international preclinical and clinical research program focused on developing innovative behavioral, biological, and pharmacological treatment approaches for cocaine, methamphetamine, opiate, cannabis, and tobacco use disorders. The Director, DTMC also oversees the development and administration of an international program of studies to improve the treatment of HIV/AIDS in drug abusing populations. The Director, DTMC, provides high-level leadership and management for the Division’s research programs, including supervisory oversight of DTMC’s resource allocation, six branches, and a staff of 28 extramural scientists and 4 administrative staff. The current DTMC budget is approximately $170M.
The successful candidate will possess an M.D., and/or Ph.D. degree, and will have knowledge of neuropsychopharmacology and experience in medications development, including the design and execution of multi-site clinical trials. Managerial experience in medications development within the biotechnology or pharmaceutical sectors is highly desirable. The individual must also have demonstrated ability to manage personnel, budgets, and timelines across multiple fiscal years.
The successful candidate for this position will be appointed at a salarycommensurate with his/her qualifications. Full federal benefits will be provided including leave, health and life insurance, retirement, and savings plan (401k equivalent).
Equal Opportunity Employment
Selection for this position will be based solely on merit, with no discrimination for non-merit reasons such as race, color, religion, gender, sexual orientation, national origin, political affiliation, marital status, disability, age, or membership or non-membership in an employee organization. The NIH encourages the application and nomination of qualified women, minorities, and individuals with disabilities.
Standards of Conduct/Financial Disclosure
The National Institutes of Health inspires public confidence in our science by maintaining high ethical principles. NIH employees are subject to Federal government-wide regulations and statutes, as well as agency-specific regulations described at the NIH Ethics Website. We encourage you to review this information. The position is subject to a background investigation and requires the incumbent to complete a public financial disclosure report prior to the effective date of the appointment.
Applicants who have completed part or all of their education outside of the U.S. must have their foreign education evaluated by an accredited organization to ensure that the foreign education is equivalent to education received in accredited educational institutions in the United States. We will only accept the completed foreign education evaluation. For more information on foreign education verification. For more information on Foreign Education verificaiton, visit the National Association of Credential Evaluation Services (NACES) website. Verification must be received prior to the effective date of the appointment.
NIH provides reasonable accommodations to applicants with disabilities. If you require reasonable accommodation during any part of the application and hiring process, please notify us. The decision on granting reasonable accommodation will be made on a case-by-case basis.
How to Apply
Interested candidates should send a letter of interest, including a brief description of research and administrative experience, curriculum vitae, bibliography, and contact information for five individuals who can serve as references to NIDA at NIDADTMCSearch@mail.nih.gov. For further information about the position, please contact the Search Committee Chair: Dr. Christopher Austin at email@example.com.
Due to current hiring restrictions in place, HHS will need to approve the selection before a final offer may be extended.
DO NOT INCLUDE YOUR BIRTH DATE OR SOCIAL SECURITY NUMBER (SSN) ON APPLICATION MATERIALS. DHHS AND NIH ARE EQUAL OPPORTUNITY EMPLOYERS
We are dedicated to building a diverse community in our training and employment programs.
About National Institute on Drug Abuse, National Institutes of Health
The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH), the nation’s medical research agency—making important discoveries that improve health and save lives.
NIDA's mission is to lead the Nation in bringing the power of science to bear on drug abuse and addiction. This charge has two critical components. The first is the strategic support and conduct of ...research across a broad range of disciplines. The second is ensuring the rapid and effective dissemination and use of the results of that research to significantly improve prevention and treatment and to inform policy as it relates to drug abuse and addiction.